Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $113M | $-5M | $-11M | $4M | -7.6% | -5.9% | -80.7% |
| 2024 | $120M | $3M | $-56M | $-3M | -36.6% | -0.7% | -31.8% |
| 2023 | $121M | $15M | $-83M | $-7M | -38.9% | 6.1% | 456.3% |
| 2022 | $114M | $18M | $-15M | $-3M | -5.2% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 113.83 | 120.79 | 119.91 | 112.82 |
| Operating Revenue | - | 113.83 | 120.79 | 119.91 | 112.82 |
| Cost Of Revenue | - | 40.61 | 38.26 | 43.91 | 49.01 |
| Gross Profit | - | 73.22 | 82.53 | 76 | 63.81 |
| Operating Expense | - | 69.55 | 81.69 | 81.10 | 74.86 |
| Research And Development | - | 18.32 | 21.76 | 25.54 | 25.77 |
| Selling General And Administration | - | 51.23 | 59.92 | 55.56 | 49.09 |
| Total Expenses | - | 110.16 | 119.95 | 125.01 | 123.87 |
| Operating Income | - | 3.67 | 0.84 | -5.10 | -11.05 |
| Total Operating Income As Reported | - | 3.67 | 0.84 | -5.10 | -11.05 |
| EBITDA | - | 18.16 | 15.06 | 3.02 | -5.32 |
| Normalized EBITDA | - | 18.16 | 15.06 | 3.02 | -5.32 |
| EBIT | - | 3.67 | 0.84 | -5.10 | -11.05 |
| Net Interest Income | - | 0.65 | 2.31 | 2.34 | 1.74 |
| Other Income Expense | 21.10 | - | -62.19 | - | - |
| Net Non Operating Interest Income Expense | - | 0.65 | 2.31 | 2.34 | 1.74 |
| Pretax Income | - | 4.32 | 3.16 | -2.76 | -9.31 |
| Tax Provision | - | 2.12 | 6.60 | 6.06 | 0.67 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 2.20 | -3.44 | -8.83 | -9.98 |
| Net Income From Continuing And Discontinued Operation | - | -14.86 | -82.67 | -56.38 | -10.88 |
| Net Income From Continuing Operation Net Minority Interest | - | 2.20 | -3.44 | -8.83 | -9.98 |
| Net Income | - | -14.86 | -82.67 | -56.38 | -10.88 |
| Net Income Common Stockholders | - | -14.86 | -82.67 | -56.38 | -10.88 |
| Net Income Including Noncontrolling Interests | - | -14.86 | -82.67 | -56.38 | -10.88 |
| Normalized Income | - | 2.20 | -3.44 | -8.83 | -9.98 |
| Diluted NI Availto Com Stockholders | - | -14.86 | -82.67 | -56.38 | -10.88 |
| Basic Average Shares | - | 14.56 | 14.66 | 14.72 | 14.34 |
| Diluted Average Shares | - | 14.56 | 14.66 | 14.72 | 14.34 |
| Reconciled Depreciation | - | 14.49 | 14.22 | 8.12 | 5.73 |
| Reconciled Cost Of Revenue | - | 40.61 | 38.26 | 43.91 | 49.01 |
| Total Unusual Items | 21.10 | 0 | -62.19 | - | - |
| Total Unusual Items Excluding Goodwill | 21.10 | 0 | -62.19 | - | - |
| Net Income Discontinuous Operations | - | -17.06 | -79.23 | -47.56 | -0.90 |
| Special Income Charges | 21.10 | 0 | -62.19 | - | - |
| Impairment Of Capital Assets | 0 | 0 | 62.19 | - | - |
| Restructuring And Mergern Acquisition | -21.10 | 0 | 0 | - | - |
| Total Other Finance Cost | - | -0.65 | -2.31 | -2.34 | -1.74 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Anika Therapeutics, Inc.this co. | ANIK | $197M | -18.09 | 1.37 | -7.6% | -31.11 |
| Accendra Health, Inc. | ACH | $203M | -0.18 | -0.44 | 238.8% | 9.29 |
| Sanara MedTech Inc. | SMTI | $203M | -5.40 | 34.13 | -632.5% | 22.72 |
| TriSalus Life Sciences, Inc. | TLSI | $203M | -5.17 | -5.99 | 115.8% | -6.56 |
| Embecta Corp. | EMBC | $202M |
| - |
| - |
| - |
| - |
| - |
| - |
| 2.12 |
| -0.31 |
| -14.6% |
| 4.95 |
| Alector, Inc. | ALEC | $201M | - | 6.56 | -466.3% | - |
| Nkarta, Inc. | NKTX | $198M | - | 0.63 | -33.3% | - |
| Lucid Diagnostics Inc. | LUCD | $195M | - | 17.79 | -645.1% | - |
| Cartesian Therapeutics, Inc. | RNAC | $192M | -1.48 | -1.52 | 103.2% | -0.96 |
| Peer Median | - | -1.48 | 0.16 | -24.0% | 4.95 | |
Historically, Feb has averaged the highest return (+13.1%); Apr the lowest (-8.1%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.0%Negative MonthJan 2026: -3.95% | +55.6%Positive MonthFeb 2026: +55.58% | +1.0%Neutral MonthMar 2026: +0.97% | -14.1%Negative MonthApr 2026: -14.14% | +16.7%Positive MonthMay 2026: +16.71% | +0.7%Neutral MonthJun 2026: +0.69% | +31.8%Positive MonthJul 2026: +31.78% | +10.3%*Positive MonthAug 2026: +10.27% | — | — | — | — |
| 2025 | +3.6%Positive MonthJan 2025: +3.65% | +2.3%Positive MonthFeb 2025: +2.29% | -13.9%Negative MonthMar 2025: -13.87% | -3.3%Negative MonthApr 2025: -3.33% | -23.3%Negative MonthMay 2025: -23.26% | -5.1%Negative MonthJun 2025: -5.11% | -21.9%Negative MonthJul 2025: -21.93% | +13.6%Positive MonthAug 2025: +13.56% | +0.2%Neutral MonthSep 2025: +0.21% | +3.7%Positive MonthOct 2025: +3.72% | +1.3%Neutral MonthNov 2025: +1.33% | -2.7%Negative MonthDec 2025: -2.73% |
| 2024 | +3.8%Positive MonthJan 2024: +3.80% | +3.2%Positive MonthFeb 2024: +3.23% | +4.6%Positive MonthMar 2024: +4.61% | +1.9%Neutral MonthApr 2024: +1.93% | -0.9%Neutral MonthMay 2024: -0.93% | -1.2%Neutral MonthJun 2024: -1.25% | +7.6%Positive MonthJul 2024: +7.58% | -5.7%Negative MonthAug 2024: -5.69% | -3.9%Negative MonthSep 2024: -3.89% | -30.7%Negative MonthOct 2024: -30.73% | +3.6%Positive MonthNov 2024: +3.57% | -7.1%Negative MonthDec 2024: -7.11% |
| 2023 | +4.8%Positive MonthJan 2023: +4.76% | +2.2%Positive MonthFeb 2023: +2.23% | -9.4%Negative MonthMar 2023: -9.40% | -10.7%Negative MonthApr 2023: -10.65% | +5.6%Positive MonthMay 2023: +5.57% | -4.1%Negative MonthJun 2023: -4.10% | -10.2%Negative MonthJul 2023: -10.20% | -23.5%Negative MonthAug 2023: -23.49% | +4.4%Positive MonthSep 2023: +4.37% | +4.7%Positive MonthOct 2023: +4.67% | +12.4%Positive MonthNov 2023: +12.36% | +3.4%Positive MonthDec 2023: +3.42% |
| 2022 | -11.2%Negative MonthJan 2022: -11.25% | +2.2%Positive MonthFeb 2022: +2.20% | -22.7%Negative MonthMar 2022: -22.74% | -14.3%Negative MonthApr 2022: -14.26% | +1.0%Neutral MonthMay 2022: +0.98% | +2.7%Positive MonthJun 2022: +2.67% | +4.7%Positive MonthJul 2022: +4.66% | -3.3%Negative MonthAug 2022: -3.25% | +5.3%Positive MonthSep 2022: +5.31% | +19.4%Positive MonthOct 2022: +19.41% | +11.0%Positive MonthNov 2022: +10.98% | -6.2%Negative MonthDec 2022: -6.15% |
| 2021 | — | — | — | — | +16.1%Positive MonthMay 2021: +16.10% | -7.2%Negative MonthJun 2021: -7.20% | -7.3%Negative MonthJul 2021: -7.30% | +7.5%Positive MonthAug 2021: +7.48% | -1.3%Neutral MonthSep 2021: -1.32% | -2.1%Negative MonthOct 2021: -2.14% | -6.1%Negative MonthNov 2021: -6.05% | -8.4%Negative MonthDec 2021: -8.43% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
